Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer.

C M Rudin,A Cervantes,A Dowlati,B Besse,B Ma,D B Costa, P Schmid,R Heist, V M Villaflor,J Spahn,S Li,E Cha,G J Riely, S Gettinger

ESMO open（2023）

引用 3|浏览55

暂无评分

摘要

Atezolizumab combined with erlotinib demonstrated a tolerable safety profile and encouraging, durable clinical activity in patients with advanced EGFR mutation-positive NSCLC.

查看译文

关键词

EGFR-mutant NSCLC,PD-L1 inhibitor,immune checkpoint inhibitor,tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要